Tate & Lyle shares fall 0.2% as group maintains full-year guidance
For the six months ended 30 September, revenue reached £1.04 billion, an increase of 1% at constant exchange rates. Volume and product mix contributed growth of 3%, while pricing declined by 2%.
Adjusted EBITDA totalled £197 million. Adjusted pre-tax profit dropped 18% to £102 million, and adjusted earnings per share decreased 17% to 17.5p. On a statutory basis, pre-tax profit declined 37% to £46 million, while diluted earnings per share fell by half to 6.3p.
Regional revenue, measured at constant exchange rates, grew 1% in the Americas and 7% in Asia Pacific. Europe, the Middle East and Africa recorded a 4% decline. Tate & Lyle attributed pressure on profitability to increased energy and other costs, especially in Europe, the Middle East and Africa, together with strategic pricing measures and spending on capabilities.
Free cash flow reached £100 million, up £2 million. Net debt stood at £959 million, an increase of £20 million since the end of March. The interim dividend was raised to 6.8p per share, up 0.2p.
For the financial year ending in March 2027, Tate & Lyle still forecasts modest revenue growth, with a greater contribution expected in the second half. It expects EBITDA to remain broadly unchanged before an approximately US$20 million impact from rescheduling the consolidation of its bio-gums capacity.
The company plans to pass higher costs through to customers when renewing agreements for 2027. It also intends to pursue savings through productivity improvements and procurement.
